Media Room
Board of Directors
- Philippe Chambon, M.D., Ph.D., Managing Director, New Leaf Partners, LLC
- Darren W. Cohen
- Rose Crane
- Tom Harrison, Chairman and CEO, Diversified Agency Service (Division of Omnicom Group)
- Patrick Jones, Chairman, Lattice Semiconductor Corporation
- Gilbert Kliman, M.D., Managing Director, InterWest Partners
- John Voris, Chairman, Regenesis Biomedical
- Mark Wan, Partner, Three Arch Partners
Dr. Philippe O. Chambon
Philippe O. Chambon has served on the Epocrates board of directors since August 2000. Since July 2005, Dr. Chambon has served as a Managing Director of New Leaf Venture Partners, a venture capital firm spun off from Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Dr. Chambon holds an M.D. and a Ph.D. from the University of Paris and an M.B.A. from Columbia University. Dr. Chambon also serves as a director of Auxilium Pharmaceuticals, Inc., NxStage Medical, Inc. and several private biotechnology companies.
Darren W. Cohen
Darren W. Cohen joined the Epocrates Board of Directors in December 2008. Darren is a Vice President at Goldman Sachs in the firm's Principal Strategic Investments group. Before returning to Goldman Sachs in January 2007, Darren was a Senior Analyst at Calypso Capital Management, a long-short equity hedge fund. Darren has also served as an Executive Director in Investment Research for Goldman Sachs in London. Darren graduated summa cum laude from Emory University with a B.A. in Philosophy and Political Science.
Rose Crane
CEO
Before joining Epocrates, Rose Crane spent over 25 years in the pharmaceutical industry in a variety of leadership roles. Most recently, Rose was a Company Group Chairman at Johnson and Johnson, where she managed the OTC/Nutritional business worldwide. Her group's acquisition of Pfizer Consumer Healthcare resulted in Johnson & Johnson becoming the largest OTC company worldwide, with a well balanced portfolio of diverse brands. She also served as a Company Group Chairman for the consumer, specialty and nutritionals business during her tenure.
Prior to Johnson and Johnson, Rose was President of the U.S. Primary Care division for Bristol-Myers Squibb, where she was responsible for all sales, marketing, regulatory and compliance operations, managing a $6.5 billion budget. During her time at Bristol Myers Squibb, Rose also held a variety of marketing, sales and product management leadership positions.
Rose holds a B.A. from SUNY Oswego and an M.B.A. from Kent State University.
Thomas L. Harrison
Thomas L. Harrison has served on the Epocrates board of directors since January 2002. Thomas has served as Chairman and Chief Executive Officer of the Diversified Agency Services division of Omnicom Group, Inc., an advertising and marketing company, since May 1998. Thomas holds an M.S. in cell biology and physiology from West Virginia University. He also serves as a director of The Morgan's Hotel Group.
Patrick S. Jones
Patrick S. Jones joined the Epocrates board of directors in October 2005. Pat has been a private financial consultant since March 2001. Pat holds a B.A. from the University of Illinois and an M.B.A. from St. Louis University. He also serves as Chairman of the Board of Lattice Semiconductor, Inc. and serves as a director of Genesys SA and several private companies.
Dr. Gilbert H. Kliman
Gilbert H. Kliman has served on the Epocrates board of directors since September 1999. Dr. Kliman has been a general partner of InterWest Partners, a private equity firm, since 1999. Dr. Kliman holds a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from the Stanford Graduate School of Business. He also serves as a director of Intralase Corp. and several private life science companies.
John E. Voris
John E. Voris has served on the Epocrates Board of Directors since June 2000. He currently also serves on the boards of Regenesis Biomedical, where he is Chairman, and InfuSystem, a public company. From 2005-2007, John was CEO of HAPC, Inc., a special purpose acquisition company, that acquired InfuSystem. John served as President and Chief Executive Officer of Epocrates for four years (June 2000-2004). Prior to Epocrates, John spent nearly three decades at Eli Lilly and Company serving in a variety of leadership roles. John holds a B.A. and an M.B.A. from the Kelley School of Business at Indiana University.
Mark A. Wan
Mark A. Wan has served on the Epocrates board of directors since September 1999. Mark has been a partner of Three Arch Partners, a venture capital firm, since 1993. He holds a B.A. and a B.S. from Yale University and an M.B.A. from Stanford University's Graduate School of Business. He has served on the boards of many private and public medical companies.